NEW YORK CITY, New York: Chinese suppliers that once fueled America's gray market for cut-price weight-loss drugs are pivoting toward making legitimate generics, as U.S. regulators crack down on compounding pharmacies and shipments of raw ingredients plunge.
For the past two years, companies in China shipped enough semaglutide and tirzepatide, the key ingredients in Novo Nordisk's Wegovy and Eli Lilly's Zepbound
© 2025 Sedmasila All rights reserved.